Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Hyperthermia × Dacarbazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hodgkin Disease 33 Melanoma 20 Lymphoma 8 Sarcoma 6 Neoplasm Metastasis 5 Leiomyosarcoma 3 Uveal Melanoma 2 Skin Neoplasms 2 Sarcoma, Synovial 2 Thyroid Neoplasms 1 Solitary Fibrous Tumors 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Parathyroid Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neurofibrosarcoma 1 Neuroendocrine Tumors 1 Neoplasms 1 Immunotherapy 1 Hyperthermia 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1 Hemangioendothelioma 1 Gliosarcoma 1 Glioma, Subependymal 1 Glioma 1

Interventions

Diathermy 17 Radiotherapy 10 Drug Therapy 4 Cisplatin 4 Radiation 3 Immune Checkpoint Inhibitors 3 Fluorouracil 3 Brachytherapy 3 tislelizumab 2 Surgical Procedures, Operative 2 Immunotherapy 2 Conization 2 spartalizumab 1 anlotinib 1 Solutions 1 Radiation Dose Hypofractionation 1 Patient Reported Outcome Measures 1 Paclitaxel 1 Mitomycin 1 Ifosfamide 1 Hyperthermic Intraperitoneal Chemotherapy 1 Hyperthermia, Induced 1 Hydrogen Peroxide 1 Gemcitabine 1 Folfox protocol 1 Doxorubicin 1 Docetaxel 1 Dacarbazine 1 Cytoreduction Surgical Procedures 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06835049 2025-12-30

TNT-HYPE

Swiss Cancer Institute

Phase 2 Recruiting

Hyperthermia, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡